Becton Dickinson and Company (BDX) Stock Price, Quote & News

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 201 847 6800

Website: www.bd.com

Address:

1 Becton Drive, Franklin Lakes, United States

11thestate Feb. 4 at 1:08 PM

If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BDX — how you can actually recover something: https://11th.com/cases/bdx-shareholder-settlement

0 · Reply

DukeSecurities Feb. 4 at 11:28 AM

$BDX is a medical device company with a vast portfolio; product innovation and margin improvement are ongoing initiatives.

0 · Reply

ZacksResearch Feb. 2 at 6:01 PM

Closed-loop recycling in medtech — quietly bullish for $BDX ♻️👀 BD completed a pilot with Envetec, demonstrating that polystyrene Petri dishes can be safely recycled into new medical-grade feedstock, showcasing a practical closed-loop solution for lab plastics. See how this innovation could matter long term 👉 https://www.zacks.com/stock/news/2827256/bd-envetec-showcase-closed-loop-recycling-solution-for-lab-plastics?cid=sm-stocktwits-2-2827256-teaser-31555&ADID=SYND_STOCKTWITS_TWEET_2_2827256_TEASER_31555

0 · Reply

ZacksResearch Feb. 2 at 5:01 PM

$BDX takes a step toward a greener future with its successful recycling pilot! ♻️ BD's initiative with Envetec Sustainable Technologies shows potential for lab plastics to be recycled and reused without quality loss, reinforcing the company's sustainability narrative. 🚀 This move could position BDX as an innovator in sustainable healthcare solutions, despite no immediate revenue impact. See what makes the investment case strong for BDX 👉 https://www.zacks.com/stock/news/2827256/bd-envetec-showcase-closed-loop-recycling-solution-for-lab-plastics?cid=sm-stocktwits-2-2827256-body-31532&ADID=SYND_STOCKTWITS_TWEET_2_2827256_BODY_31532

0 · Reply

Estimize Feb. 2 at 3:01 PM

Wall St is expecting 3.31 EPS for $BDX Q2 [Reporting 04/30 BMO] http://www.estimize.com/intro/bdx?chart=historical&metric_name=eps&utm_cont

0 · Reply

PickAlpha Jan. 28 at 12:53 PM

PickAlpha Morning Report - Company News: 2026.01.28 News Analysis - 1/6: BD sets record date and final terms for tax‑efficient spin-off and Reverse Morris Trust merger with Waters | View: Transaction terms, tax ruling, and approvals reduce deal risk and clarify value transfer… $BDX $WAT $XLV $XHE

0 · Reply

ZacksResearch Jan. 27 at 7:38 PM

$BDX launches BD Research Cloud 7.0 — What does it mean for investors? 🚀 🔬 AI-driven improvements in flow cytometry 💡 Boosts research quality and productivity 📈 Shares up 11.2% in the last six months, in contrast to the industry’s decline Discover the full potential of this launch here 👉 https://www.zacks.com/stock/news/2823629/bdx-introduces-bd-research-cloud-70-for-advanced-flow-cytometry?cid=sm-stocktwits-2-2823629-body-30556&ADID=SYND_STOCKTWITS_TWEET_2_2823629_BODY_30556

0 · Reply

ZacksResearch Jan. 27 at 6:38 PM

$BDX just made a smart AI move in flow cytometry — and it matters 🧠 BD Research Cloud 7.0 launches with the AI-powered Horizon Panel Maker, pushing automation, data intelligence, and productivity higher for advanced flow cytometry workflows. Quiet innovation like this can drive long-term value. See what this upgrade means for BDX 👉 https://www.zacks.com/stock/news/2823629/bdx-introduces-bd-research-cloud-70-for-advanced-flow-cytometry?cid=sm-stocktwits-2-2823629-teaser-30545&ADID=SYND_STOCKTWITS_TWEET_2_2823629_TEASER_30545

0 · Reply

Investor6 Jan. 27 at 3:55 PM

$WAT Waters Corp. Tuesday announced that its shareholders have approved the issuance of Waters common stock to shareholders of Becton, Dickinson and Company $BDX as part of the proposed combination of the latter's Biosciences & Diagnostic Solutions business with the company. With this approval, the company is planning to close the transaction on February 9, 2026. In other M&A news, BARK received a second buyout offer by Marcus Lemonis for $1.10 per share, with the first from the CEO standing at $0.90. The current sp of BARK is at $0.88.

0 · Reply

catacal_ Jan. 23 at 7:56 PM

$BDX - 2026 Annual Meeting of Shareholders on Tue. Jan. 27 at 1:00 PM. Could be significant. $QQQ

0 · Reply

10 Highest Rated Dividend Kings For Generations Of Income

ABBV ABM ABT ADM BKH KMB KO

Jan 29, 2026, 6:50 AM EST - 6 days ago

BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care

Jan 27, 2026, 4:15 PM EST - 7 days ago

BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

Jan 27, 2026, 9:26 AM EST - 8 days ago

BD to Announce Financial Results for its First Quarter of Fiscal 2026

Jan 27, 2026, 9:25 AM EST - 8 days ago

BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business

WAT

Jan 27, 2026, 9:25 AM EST - 8 days ago

Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

WAT

Jan 25, 2026, 10:11 PM EST - 9 days ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BKH

Jan 23, 2026, 6:50 AM EST - 12 days ago

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Jan 21, 2026, 6:50 AM EST - 14 days ago

BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

Jan 19, 2026, 8:10 PM EST - 15 days ago

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

DD MSFT ORCL PFE PH Q SLB

Jan 15, 2026, 12:38 PM EST - 19 days ago

Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026

Jan 15, 2026, 6:50 AM EST - 20 days ago

BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System

Jan 14, 2026, 6:50 AM EST - 21 days ago

BD Names Shawn Bevec as Senior Vice President of Investor Relations

Jan 13, 2026, 6:50 AM EST - 22 days ago

BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

Jan 12, 2026, 4:20 PM EST - 22 days ago

MoneyShow's Best Investment Ideas For 2026: Part 2

AXSM BRO BX CALM

Jan 12, 2026, 4:15 PM EST - 22 days ago

BD To Host Virtual 2026 Annual Meeting of Shareholders

Jan 7, 2026, 12:00 PM EST - 27 days ago

Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In'

MA UNP

Jan 6, 2026, 1:48 PM EST - 4 weeks ago

Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst

Jan 5, 2026, 6:50 AM EST - 4 weeks ago

BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

Dec 31, 2025, 8:47 AM EST - 5 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 28, 2025, 6:44 AM EST - 5 weeks ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BKH

Dec 18, 2025, 6:50 AM EST - 6 weeks ago

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

Dec 17, 2025, 2:20 PM EST - 6 weeks ago

The Magnificent 7 Are So Yesterday. These Are AI's Next Big Winners

BME

Dec 15, 2025, 4:40 PM EST - 7 weeks ago

BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec

Dec 4, 2025, 6:50 AM EST - 2 months ago

BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories

Dec 3, 2025, 6:50 AM EST - 2 months ago

BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes

Nov 29, 2025, 8:02 AM EST - 2 months ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Nov 24, 2025, 6:50 AM EST - 2 months ago

BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

Nov 17, 2025, 4:30 PM EST - 2 months ago

BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

Nov 17, 2025, 6:50 AM EST - 2 months ago

BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification

Nov 13, 2025, 6:50 AM EST - 2 months ago

Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH

Nov 12, 2025, 6:50 AM EST - 3 months ago

BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

Nov 6, 2025, 3:26 PM EST - 3 months ago

Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript

Nov 6, 2025, 1:11 PM EST - 3 months ago

Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal

Nov 6, 2025, 8:58 AM EST - 3 months ago

Becton sees 2026 profit slightly above estimates on strong demand for drug delivery devices

Nov 6, 2025, 6:30 AM EST - 3 months ago

BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Nov 6, 2025, 6:25 AM EST - 3 months ago

BD Board Increases Dividend for 54th Consecutive Year

Nov 4, 2025, 6:50 AM EST - 3 months ago

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

Nov 3, 2025, 6:50 AM EST - 3 months ago

BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR™ System

Nov 1, 2025, 11:15 PM EDT - 3 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ABBV ADP AEP AIZ AOS ATO BRO

Nov 1, 2025, 10:25 AM EDT - 3 months ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Oct 29, 2025, 5:11 AM EDT - 3 months ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BKH

Oct 22, 2025, 6:52 AM EDT - 3 months ago

BD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States

Oct 21, 2025, 11:07 AM EDT - 3 months ago

It's time to scoop up undervalued stocks in this critical sector of the economy

BSX ISRG SYK BDYN BIO FEGE JGLO

Oct 20, 2025, 9:30 AM EDT - 3 months ago

Becton, Dickinson and Company: A Dividend Idea With Diverse Medtech Portfolio To Meet Future Demand

Oct 20, 2025, 6:50 AM EDT - 3 months ago

BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

Oct 16, 2025, 9:06 AM EDT - 3 months ago

Fiduciary Management: A Few Holdings That We Find Compelling Over The Long Term

OMF

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Buy These 3 Dividend Aristocrats Now For Growing Passive Income

CVX SHW

Oct 16, 2025, 6:50 AM EDT - 3 months ago

BD Looks Ahead to the Next Era of Manufacturing Excellence in Broken Bow, NE and Celebrates 65 Years of Innovation in the Region

11thestate Feb. 4 at 1:08 PM

0 · Reply

DukeSecurities Feb. 4 at 11:28 AM

$BDX is a medical device company with a vast portfolio; product innovation and margin improvement are ongoing initiatives.

0 · Reply

ZacksResearch Feb. 2 at 6:01 PM

0 · Reply

ZacksResearch Feb. 2 at 5:01 PM

0 · Reply

Estimize Feb. 2 at 3:01 PM

Wall St is expecting 3.31 EPS for $BDX Q2 [Reporting 04/30 BMO] http://www.estimize.com/intro/bdx?chart=historical&metric_name=eps&utm_cont

0 · Reply

PickAlpha Jan. 28 at 12:53 PM

0 · Reply

ZacksResearch Jan. 27 at 7:38 PM

0 · Reply

ZacksResearch Jan. 27 at 6:38 PM

0 · Reply

Investor6 Jan. 27 at 3:55 PM

0 · Reply

catacal_ Jan. 23 at 7:56 PM

$BDX - 2026 Annual Meeting of Shareholders on Tue. Jan. 27 at 1:00 PM. Could be significant. $QQQ

0 · Reply

AStrokeOfLuck Jan. 23 at 7:24 PM

$NVO $BDX $WST

1 · Reply

Guntz Jan. 23 at 3:34 PM

$BDX What happened here?

1 · Reply

ZacksResearch Jan. 23 at 6:00 AM

FDA green light for BD — a new medtech catalyst in play 👀🩺 $BDX secured FDA 510(k) clearance for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. See why this approval matters for BD 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29977&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29977

0 · Reply

ZacksResearch Jan. 22 at 7:18 PM

$BDX is doubling down on biologics — and this move looks strategic. 🚀 BD is expanding its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, directly targeting rising demand for large-volume subcutaneous self-injection in the growing biologics market. See why this partnership expansion matters 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-teaser-30142&ADID=SYND_STOCKTWITS_TWEET_2_2821310_TEASER_30142

0 · Reply

ZacksResearch Jan. 22 at 6:18 PM

$BDX expands partnership with Ypsomed — what it means for investors! 🤝 BDX shares rose 1.4% as it announced the expansion of its partnership with Ypsomed to include a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, aligning with Ypsomed’s autoinjector. This move positions BD to capture growth in the biologics market, with samples expected by mid-2026. 📈 Discover the full impact here 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-body-30127&ADID=SYND_STOCKTWITS_TWEET_2_2821310_BODY_30127

0 · Reply

ZacksResearch Jan. 22 at 6:00 AM

$BDX receives FDA clearance for innovative breast biopsy system — what's next for the stock? 🤔 The EnCor EnCompass system offers multi-modality use and advanced features, strengthening BD's leadership in women’s health diagnostics. But shares have dipped 2.4% since the announcement. 📉 Opportunity assessment here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29968&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29968

0 · Reply

ZacksResearch Jan. 21 at 7:15 PM

$BDX just cleared a key regulatory hurdle — and it matters for what’s next. ✅ BD received FDA 510(k) approval for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. Incremental innovation with real clinical impact. Get the full details here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29967&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29967

0 · Reply

ZacksResearch Jan. 21 at 6:15 PM

$BDX just got FDA clearance for an advanced breast biopsy system! 🚀 The EnCor EnCompass System, launching in 2026, promises multi-modality use and precision that could strengthen BDX's leadership in women's health diagnostics. Discover how this could support BDX's long-term growth strategy 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29964&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29964

0 · Reply

TalkMarkets Jan. 18 at 3:57 PM

3 Top #Dividend #Stocks For 2026 $BDX $CTAS $NDSN https://talkmarkets.com/content/stocks--equities/3-top-dividend-stocks-for-2026?post=550859

0 · Reply

COYOTEofWS Jan. 15 at 11:29 PM

$BDX if this can get above $210 it should be fairly clear to push on up to 230. GLTA ✌️

0 · Reply

JFDI Jan. 14 at 7:35 PM

$BDX ..

0 · Reply

DividendPower Jan. 14 at 2:49 PM

3 Top Dividend Stocks For 2026 https://www.dividendpower.org/top-dividend-stocks-2026/ $BDX $NDSN $CTAS @SureDividend

0 · Reply

Market Cap	57.97B
Revenue (ttm)	21.84B
Net Income (ttm)	1.68B
EPS (ttm)	N/A
PE Ratio	13.95
Forward PE	13.55
Profit Margin	7.68%
Debt to Equity Ratio	0.69

Volume	2,887,200
Avg Vol	1,895,114
Day's Range	N/A - N/A
Shares Out	284.91M
Stochastic %K	84%
Beta	0.23
Analysts	Sell
Price Target	$205.40